Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc., based in Durham, North Carolina, is a pioneering biotechnology company dedicated to enhancing life through advanced genome editing. The company employs its proprietary genome editing platform, ARCUS, to develop innovative product candidates aimed at treating human diseases and offering solutions in food and agriculture.
ARCUS, distinguished by its compact size, enables the delivery of gene edits to a broader range of cells and tissues using both viral and non-viral methods. This versatility makes it a robust tool in Precision BioSciences' mission to address various health conditions and agricultural challenges.
The company has recently made significant strides in its projects, partnering with multiple organizations to expand its research and product development capabilities. These collaborations have been pivotal in propelling forward the potential applications of ARCUS technology.
Precision BioSciences is actively engaged in several cutting-edge projects that underscore its commitment to innovation. The company's financial health is reflected in its consistent investment in research and development, ensuring sustained growth and advancement in its technology.
Latest News:
- Source: iECURE, Inc.
- Source: Precision BioSciences, Inc.
- Source: Precision BioSciences
Precision BioSciences, Inc. (Nasdaq: DTIL) reported their first quarter 2024 financial results and provided a business update. The company is focused on advancing its wholly owned gene editing programs for Hepatitis B virus and primary mitochondrial myopathy. Precision also exercised the option to return three preclinical programs for internal development or with partners. They monetized CAR T assets through licensing deals and completed a $40 million common stock offering to extend cash runway into H2 2026. Financially, Precision had $137.8 million in cash and cash equivalents as of March 31, 2024, with total revenues of $17.6 million for the quarter. Research and development expenses increased to $13.3 million, while general and administrative expenses decreased to $8.4 million. Net income from continuing operations was $8.6 million for the quarter.
Precision BioSciences, Inc. announced a private placement where the company will issue and sell 25,000 shares of common stock to its senior leadership team, including the CEO, at a price of $12.00 per share, totaling $300,000. The Private Placement is set to close on May 8, 2024, with the net proceeds intended for research and development initiatives.
Precision BioSciences, Inc. (Nasdaq: DTIL) will report its first-quarter financial results on May 13, 2024. The company utilizes its ARCUS® platform for gene editing therapies, including elimination, insertion, and excision.
Precision BioSciences, Inc. (Nasdaq: DTIL) announced that its partner iECURE has received FDA Fast Track designation for ECUR-506 to treat Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency. The Fast Track designation expedites the review process for therapeutics addressing unmet medical needs. ECUR-506 also received Rare Pediatric Disease and Orphan Drug designations.
iECURE, Inc. has received Fast Track designation from the FDA for ECUR-506, an in vivo gene insertion program to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency. The designation helps expedite the review process for therapies addressing unmet medical needs. The company's OTC-HOPE study is open for enrollment in the UK, with sites in the US and Australia to follow, focusing on safety, efficacy, and other endpoints.
Precision BioSciences, Inc. announced a late-breaking poster presentation at the European Association for Study of the Liver Congress 2024, showcasing preclinical safety data for their clinical candidate PBGENE-HBV for the treatment of chronic hepatitis B. The data supports the progression of the gene editing program towards potential clinical trials and regulatory filings in 2024.
FAQ
What is the current stock price of Precision Biosciences (DTIL)?
What is the market cap of Precision Biosciences (DTIL)?
What does Precision BioSciences, Inc. do?
Where is Precision BioSciences, Inc. located?
What is ARCUS?
What are some recent achievements of Precision BioSciences?
What is the focus of Precision BioSciences' current projects?
How does ARCUS differ from other genome editing tools?
Who are some partners of Precision BioSciences?
What kind of financial strategy does Precision BioSciences employ?
What is the significance of Precision BioSciences' work in agriculture?
How does Precision BioSciences contribute to human health?
